Provided is a method for producing an artificial recombinant virus of the family Reoviridae, the method comprising the steps of: (1) introducing a FAST protein expression vector and/or a capping enzyme expression vector into host cells; (2) introducing a vector containing expression cassettes for individual RNA genome segments of a virus or introducing a set of single-stranded RNA transcripts from the expression cassettes into host cells; and (3) culturing the host cells.

The method of the present invention allows more efficient production of an artificial recombinant virus of the family Reoviridae as compared with conventional methods and allows artificial recombinant rotavirus production without using a helper virus.

The present invention relates to an attenuated reovirus-based vaccine composition and a use thereof, the attenuated reovirus, according to the present invention, having the 251st to 455th amino acids of a sigma-1 protein of a capsid truncated such that when an epitope of an antigenic protein inducing cancer or infectious disease is introduced to the truncated site of the sigma-1 protein, the epitope of the antigenic protein is stably expressed in a cell, and thus the effect is gained of exhibiting an immune response such as producing a neutralizing antibody or inducing cell-mediated immunity. As such, the present invention is expected to be usefully employable as a vaccine composition for cancer or infectious disease by introducing the epitope of the antigenic protein to the truncated site of the sigma-1 protein of the attenuated reovirus according to the present invention.

A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin targeting peptide which is derived from cypovirus polyhedrin and binds to cypovirus polyhedrin. The polyhedrin targeting peptide is described as a C-terminal portion of cypovirus polyhedrin and as C-terminal portion of cypovirus polyhedrin absent all or part of the N-terminal H1 helix sequence. Vectors and cells capable of expressing the fusion proteins are also provided. The fusion proteins fold with cypovirus polyhedrin to form modified complexes, polyhedra/microcubes useful in myriad applications, including as a platform technology for prophylactic or therapeutic vaccinations, therapeutics and diagnostics, including vaccines, therapeutics and diagnostics etc. employing membrane proteins.

Attenuated G9P[6] rotavirus is disclosed herein. In some embodiments, pharmaceutical compositions are disclosed that include an attenuated G9P[6] rotavirus, or a component thereof. These compositions can be used to induce an immune response, such as a protective immune response, to a rotavirus. The compositions can be used as vaccines, such as for children (infants), for example in a prime boost strategy.

A broad-spectrum vaccine against avian Reovirus is disclosed, which is effective in reducing the infection of avian Reovirus in an avian target. The vaccine comprises antigenic material derived from avian Reovirus of two genotype groups: 1 and 4, as defined herein. This vaccine is effective against all avian Reoviruses, homologous or heterologous to the vaccine, including recent virulent break-through strains.

A fusion protein is provided which is based on a self-assembling gene-regulatory NSP10 protein and a protein or peptide capable of being fused to NSP10 without interfering with the assembly or aggregation of the resulting fusion protein. The disclosure also relates to any nanoparticle formed thereby whether complete or not, and methods for the use of the NSP10 fusion protein are also disclosed, including use as vaccines for any indication in humans or animals, therapeutic methods involving the use of the fusion proteins such as using the protein to targeted an antibody or receptor, such as for treating or diagnosing cancer, bio-sensors using the fusion protein, or the use of the fusion proteins in cell sorting or any imaging application.

Arbovirus carries an altered furin cleavage site that results in enhanced cleavage of a precursor polyprotein, such as, prE2 or prM. Dengue virus particles can have an amino acid alteration within amino acids 80-130 of prM. Zika virus particles can have alterations at amino residues at and/or about the furin cleavage site. The virus can be produced in insect cells. The virus does not form progeny virus in mammal cells.

Compositions and methods are provided relating to rotavirus serotypes and antibodies that bind to human rotavirus and modifications thereto which enhance the immunogenicity of the rotavirus protein for vaccine development with respect to the generation of a neutralizing immune response. Further disclosed are methods of using the antibodies for treating a rotavirus-mediated disease in a subject.

A fusion protein comprising an N-terminal portion and a C-terminal portion, wherein the N-terminal portion is a heterologous protein of interest which includes membrane proteins and antigens and the C-terminal portion is a polyhedrin targeting peptide which is derived from cypovirus polyhedrin and binds to cypovirus polyhedrin. The polyhedrin targeting peptide is described as a C-terminal portion of cypovirus polyhedrin and as C-terminal portion of cypovirus polyhedrin absent all or part of the N-terminal H1 helix sequence. The polyhedrin targeting peptide may also be derived from silkworm cypovirus (BmCPV) polyhedrin. In one example, the polyhedrin targeting peptide comprises the peptide sequence set forth in SEQ ID NO: 14, SEQ ID NO:13 or SEQ ID NO:12 or a functional variant thereof. Vectors and cells capable of expressing the fusion proteins are also provided. The fusion proteins fold with cypovirus polyhedrin to form modified complexes, polyhedra/microcubes useful in myriad applications, including as a platform technology for prophylactic or therapeutic vaccinations, therapeutics and diagnostics, including vaccines, therapeutics and diagnostics etc. employing membrane proteins.

A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (CPV). Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto. Methods of using same to elicit an immune response.